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phasizing which clinical trials need to be conducted within the next 3 
years to reduce NSCLC-related morbidity/mortality, would be of value.
Methods: The SLC in Lung Cancer, an initiative of the CCCG to 
establish and advance national clinical research priorities in lung can-
cer, is a multidisciplinary group with representation from cooperative 
groups, Specialized Programs of Research Excellence, cancer centers, 
and leading academic and community institutions. The initial meeting 
of the SLC in Lung Cancer was held in Philadelphia, Pennsylvania, 
on November 13-14, 2005, followed by a scientiﬁc dialogue with as-
sociated constituencies (patient advocacy groups and pharmaceutical 
companies engaged in lung cancer drug development) in Santa Monica, 
California on January 25-26, 2006. This report summarizes the primary 
research priorities identiﬁed during this series of meetings.
Results: Eight primary research priorities were identiﬁed:
Clinical trial design/accrual
• Identify and address barriers to accrual into adjuvant trials, building 
awareness among patients and clinicians
• Evaluate new measures of response
• Support novel agent development and associated biomarker valida-
tion
• Revisit trial design approach for novel agents with consideration of 
traditionally low accrual rates in early-stage NSCLC
• Ensure adequate funding of trials and correlative studies
Screening and staging
• Integrate emerging CT scan data into screening paradigms
• Prospectively evaluate molecular screening tests
• Develop new molecular imaging and staging approaches
Conclusions: The SLC in Lung Cancer has identiﬁed several priority 
research areas to be addressed in the next 3-5 years, which will guide 
continued CCCG for advancing NSCLC research. The recommenda-
tions rely on adequate clinical trial accrual and ongoing cooperative 
group support.
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Background: Bone metastases are an important emerging problem in 
patients with lung cancer and are leading to increasing consumption of 
health care resources. 
Objectives: To assess the epidemiology, the management strategies and 
the costs of bone metastases in lung cancer; to model the management 
of these patients by a Markov model in order to evaluate the effective-
ness of different therapeutic strategies.
Methods: prospective, national, multicentric, observational, epide-
miological study planned to include 500 patients between may 2006 
and may 2007, with a one year follow up, a monthly report of skeletal-
related events and resources consumptions. The economic analysis is 
limited to the direct costs with the health care payer’s perspective.
Results: At this time, 404 patients are included by 36 centres: men: 
77,2%, median age: 61 (39-84) years, non small cell lung cancer: 90%. 
Bone diagnosis metastases is made by scintigraphy (59.7%), standard 
radiology or RMI (3.4%), and bone-scan (36.9%). At inclusion the 
median number of lesions was 4; 74.4% of patients receive an analgesic 
treatment, 41.5% a biphosphonates therapy (zoledronate in 83% of 
cases), 20.5% a radiotherapy and 5%.had a bone-surgery. 
Conclusion: complete demographic, clinical and economical datas will 
be presented at the IASCL meeting.
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Background: Little is known about the patient’s and carer’s experience 
of non small cell lung cancer (NSCLC), despite a growing research in-
terest in quality of life, psychosocial aspects and unmet needs of cancer 
patients. The aim of this project is to explore and describe the NSCLC 
patient and carer perspective in terms of their needs (including unmet 
needs) and quality of life issues. 
Method: Focus groups were conducted with 27 patients with Stage 
IIIB/IV NSCLC recruited from seven hospitals in New South Wales 
and Queensland including public and private, metropolitan and regional 
with visiting oncology services. Focus groups with 13 carers were 
conducted in three sites. A semi-structured discussion guide was used. 
Participants were asked to discuss the needs of people with NSCLC, 
impact on families, concerns about the future, interactions with health 
care providers, experiences and expectations of patient support groups. 
Discussions were audio-taped and transcribed verbatim. 
Results: Overall, participants described high satisfaction with the 
quality of health and supportive care received. However, there was a 
range of experiences relating to the degree of engagement in “driv-
ing” or “managing” their health care: some participants were satisﬁed 
with being directed through treatment, others wanted to be “one step 
ahead” of treatment delivery. One patient was particularly fearful of his 
condition and unconnected with any support service. Patient partici-
pants expressed concerns regarding the impact of NSCLC on their 
families and, in particular, their spouses. Patients described difﬁculties 
in communicating with their spouses in discussing their thoughts, fears 
and concerns about the future. Issues discussed also included need-
ing to know “how they would die”, lack of choice regarding voluntary 
euthanasia and, for younger participants, communicating and dealing 
with the reactions of their young children. Typically, carers seemed 
to “hide” their feelings about the cancer and the impact on their lives. 
They also described putting the rest of their lives “on hold” to care for 
their partners. The lack of media attention on NSCLC (or prominence 
of adverse media around smoking and lung cancer) was a concern for 
some participants and affected the extent and quality of support they 
received from family and social networks. 
